- Science
- Clinical Trials
- Guide to Clinical Trials Your participation makes a difference
- Clinical Trials in Children Designed to improve kids' health
- Data and Results Sharing our Results
- Integrity and Transparency Building Trust
- Diversity Equity and Representation
- Plain Language Study Results Trial Result Summaries
- Expanded Access & Compassionate Use Possible Treatment Options
- Find a Trial
- Areas of Focus
- Rare Disease Smaller populations but big impact
- Internal Medicine Extending lifespans worldwide
- Inflammation & Immunology Treatment at the molecular level
- Vaccines Preventing the spread of infections
- Oncology The science of optimism
- Anti Infectives Combatting an evolving risk
- Areas of Innovation
- Gene Therapy Breakthroughs become treatments
- Medicinal Sciences The next generation of science
- Precision Medicine Developing tailored medicines
- Maternal Immunization Protecting newborns at the start
- mRNA Technology Unleashing the next wave of scientific innovations
- Diseases & Conditions
- Coronavirus Resources
- Product Pipeline
- Research Sites
- Clinical Trials
- Products
- How Drugs are Made
- Branded vs. Generic Learn the difference
- Biologics & Biosimilars Cures found in nature
- Commitment to Quality Maintaining the highest standards
- Global Supply Strategic manufacturing locations
- Manufacturing Sites Where medicine is made in the U.S.
- Medicine Safety
- Health Literacy Learning to be well
- Treatment Choices Learning about treatment decisions
- Partnering With Patients Helping others by reporting side effects
- Tips for Patients Preventing medication errors
- Reporting Adverse Events
- Counterfeiting Preventing medication errors
- Safety Data Sheets
- Product List
- Product Contacts
- PfizerPro for Professionals
- Patient Assistance Programs
- Distributors
- How Drugs are Made
- Stories
- Newsroom
- About
- People
- Executives Our senior-most leadership
- Board Members The people steering our company
- Scientists Our experts making discoveries
- Patient Stories Our patients
- Colleague Stories Our colleagues
- Responsibility
- Ethics & Compliance Each of us is responsible
- Diversity, Equity, and Inclusion Everyone has something to offer
- EHS Governance
- Environmental Sustainability Our responsiblity to the environment
- Global Impact Meeting urgent needs worldwide
- Health & Safety
- Human Rights Furthering dignity and worth
- Intellectual Property The benefits of fair competition
- Patient Advocacy & Engagement Putting Patients First
- Programs & Policies
- Grants Support for independent research
- Political Partnership Supporting like-minded organizations
- Working with Healthcare Professionals Collaboration to improve lives
- Prescription Value & Pricing How to lower patient costs
- Privacy Principles Commitment to personal data privacy
- Ready for Cures Improving Access to Medicines
- Transparency in Grants Committed to Disclosure
- Investors
- Investors Overview Information for stockholders
- Why Invest Why to join us in our mission
- Events & Presentations Calendar of upcoming events
- Financial Reports Quarterly reports and more
- Investor News Announcements about our performance
- Stock Information Charts and data
- Shareholder Services Information on stock transactions
- Corporate Governance
- Corporate Governance Overview Gaining insight into our performance
- Board Committees & Charters Defining the corporate structure
- The Pfizer Board Policies Ensuring ethical leadership
- Corporate Governance FAQs Learn more about our approach
- Contact Our Directors Email any of our Directors
- History
- Careers
- Partners
- People
Press Releases
March 2023
03.21.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts 03.16.2023 Medicines Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer 03.16.2023 Covid-19 Medicines FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ 03.14.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years 03.13.2023 Financial Investments Pfizer Invests $43 Billion to Battle Cancer 03.10.2023 Medicines Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval 03.01.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
February 2023
02.28.2023 Vaccines Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults 02.27.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 02.24.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster 02.22.2023 Medicines Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance 02.21.2023 Vaccines Vaccines U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
Resource Library
Press Kits
These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.
Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.
For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.
For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".
For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.
Contact Pfizer Media Relations
Media Contacts
United States, Canada, and Latin America
+1 212.733.1226
Europe, Middle East, and Africa
+44-(0)845.300.8033
Asia Pacific
+65.918.732.47